JAK2 and myeloproliferative neoplasm: Interestingly, another recent study (n = 7) discovered that HSP90 inhibition disrupted JAK-STAT signalling by potently decreasing JAK2 expression and the phosphorylation of STAT3 and STAT5 in patients with myeloproliferative neoplasms (40).